DE60130580D1 - Lipidmikropartikel mittels kryogenischer mikronisierung - Google Patents

Lipidmikropartikel mittels kryogenischer mikronisierung

Info

Publication number
DE60130580D1
DE60130580D1 DE60130580T DE60130580T DE60130580D1 DE 60130580 D1 DE60130580 D1 DE 60130580D1 DE 60130580 T DE60130580 T DE 60130580T DE 60130580 T DE60130580 T DE 60130580T DE 60130580 D1 DE60130580 D1 DE 60130580D1
Authority
DE
Germany
Prior art keywords
lipid microparticles
cryogenic micronization
micronization
cryogenic
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130580T
Other languages
English (en)
Other versions
DE60130580T2 (de
Inventor
Curto Maria Dorly Del
Daniela Chicco
Pierandrea Esposito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of DE60130580D1 publication Critical patent/DE60130580D1/de
Application granted granted Critical
Publication of DE60130580T2 publication Critical patent/DE60130580T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)
DE60130580T 2000-12-27 2001-12-17 Lipidmikropartikel mittels kryogenischer mikronisierung Expired - Lifetime DE60130580T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00128556 2000-12-27
EP00128556 2000-12-27
EP01125741 2001-10-26
EP01125741 2001-10-26
PCT/EP2001/014890 WO2002051386A2 (en) 2000-12-27 2001-12-17 Lipid microparticles by cryogenic micronization

Publications (2)

Publication Number Publication Date
DE60130580D1 true DE60130580D1 (de) 2007-10-31
DE60130580T2 DE60130580T2 (de) 2008-06-12

Family

ID=26071690

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130580T Expired - Lifetime DE60130580T2 (de) 2000-12-27 2001-12-17 Lipidmikropartikel mittels kryogenischer mikronisierung

Country Status (12)

Country Link
US (1) US7704525B2 (de)
JP (1) JP4748923B2 (de)
AR (1) AR032074A1 (de)
AT (1) ATE373471T1 (de)
AU (1) AU2002219198B2 (de)
CA (1) CA2431890C (de)
DE (1) DE60130580T2 (de)
DK (1) DK1345593T3 (de)
ES (1) ES2290095T3 (de)
IL (2) IL156532A0 (de)
PT (1) PT1345593E (de)
WO (1) WO2002051386A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
WO2009080699A2 (en) 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
US9505771B2 (en) * 2011-05-18 2016-11-29 Laboratories Lesvi S.L. Stable micronised monoclin form of asenapine maleate and its synthesis
DE102013224627A1 (de) 2013-11-29 2015-06-03 Andreas Lauterbach Pharmazeutische Formulierung mit Lipidmikropartikeln und Herstellungsverfahren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3024416C2 (de) 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4837381A (en) 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
AU658608B2 (en) * 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung

Also Published As

Publication number Publication date
US7704525B2 (en) 2010-04-27
AR032074A1 (es) 2003-10-22
PT1345593E (pt) 2007-10-10
ATE373471T1 (de) 2007-10-15
CA2431890C (en) 2011-05-10
JP2004529864A (ja) 2004-09-30
AU2002219198B2 (en) 2006-06-29
IL156532A0 (en) 2004-01-04
DK1345593T3 (da) 2007-12-10
JP4748923B2 (ja) 2011-08-17
IL156532A (en) 2011-04-28
WO2002051386A3 (en) 2002-10-10
US20040091522A1 (en) 2004-05-13
WO2002051386A2 (en) 2002-07-04
ES2290095T3 (es) 2008-02-16
DE60130580T2 (de) 2008-06-12
CA2431890A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
DE60235073D1 (de) Magnetfeldgenerator
DE60130841D1 (de) Phasendetektor
DE60138803D1 (de) Hochpräzise rogowski-spule
DE10195904T1 (de) Phasendetektor
DE60114484D1 (de) Verdichter
DE60228932D1 (de) Mri-gerät
DE60137169D1 (de) Entwicklungsgerät
DE60130580D1 (de) Lipidmikropartikel mittels kryogenischer mikronisierung
NO20031387D0 (no) O-substituerte 6-metyl-tramadolderivater
DE60205078D1 (de) Magnetische Anzeigevorrichtung
ITMI20000050A0 (it) Procedimento per la preparazione della 5-carbossiftalide
ATA17122000A (de) Spulenanordnung
NO20010858L (no) Fastpunktbeslag
FI20000896A (fi) Sihti
FI20002492A0 (fi) Kelarunko
ITPD20000289A1 (it) Struttura di stendibiancheria
FI20011630A0 (fi) Karsintalaitteisto
DE50110409D1 (de) Kernspintomograph
DE602004026017D1 (de) Supraleitender Magnet
SI1345593T1 (sl) Lipidni mikrodelci s kriogeno mikronizacijo
DE60225125D1 (de) Magnetische resonanz-akustografie
NO20015691A (no) Superledende spoleanordning
DE10195089D2 (de) Verdichter
DE10196106T1 (de) Bolzen-Struktur
ATA19852000A (de) Flügelmechanikständer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition